Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic
Abstract Immune-checkpoint inhibitors (ICIs) can cause inflammation and immune-related adverse events (irAEs). Although irAEs may be caused by dysregulation of cytokines, the impact of various COVID- 19-related factors on expression of ICI-related AEs remains unclear. Assessment of AEs following ICI...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12865-025-00711-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156593204690944 |
|---|---|
| author | Sakiko Kimura Hiroo Katsuya Chiho Nakashima Naoko Sueoka-Aragane Koji Hayashida Kazumi Sasaki Rintaro Sogawa Tatsuya Furuno Moriyasu Yamauchi Yoichiro Sugiyama Hirokazu Noshiro Motohiro Esaki Mitsuru Noguchi Hirokazu Takahashi Keizo Anzai Masatoshi Yokoyama Kazunari Sugita Yoshio Yamashita Atsushi Kawaguchi Shinya Kimura Chisato Shimanoe |
| author_facet | Sakiko Kimura Hiroo Katsuya Chiho Nakashima Naoko Sueoka-Aragane Koji Hayashida Kazumi Sasaki Rintaro Sogawa Tatsuya Furuno Moriyasu Yamauchi Yoichiro Sugiyama Hirokazu Noshiro Motohiro Esaki Mitsuru Noguchi Hirokazu Takahashi Keizo Anzai Masatoshi Yokoyama Kazunari Sugita Yoshio Yamashita Atsushi Kawaguchi Shinya Kimura Chisato Shimanoe |
| author_sort | Sakiko Kimura |
| collection | DOAJ |
| description | Abstract Immune-checkpoint inhibitors (ICIs) can cause inflammation and immune-related adverse events (irAEs). Although irAEs may be caused by dysregulation of cytokines, the impact of various COVID- 19-related factors on expression of ICI-related AEs remains unclear. Assessment of AEs following ICI administration during the COVID- 19 pandemic may provide valuable insights that enable optimization of patient selection, thereby maximizing the benefits of ICI therapy. The aim of this study was to investigate the actual occurrence of severe AEs after ICI administration during the COVID- 19 pandemic. The medical records of patients who received ICI at Saga University Hospital were examined retrospectively. The primary endpoint was the incidence of all AEs ≥ Grade 3 that occurred after ICI administration. The survey period, from Jan 2020 to Dec 2022, was divided into an earlier (Jan 2020–March 2021) and a later (April 2021–Dec 2022) period. AEs with a clear cause other than ICI were excluded from the analysis. A total of 527 patients were included in the analysis, with a median follow-up of 422 days. During the COVID- 19 pandemic, the incidence of AEs ≥ Grade 3 after ICI administration was 52.8%. The incidence of AEs ≥ Grade 3 AEs after ICI administration was significantly higher during the later period [23.4% (57/244) in the earlier period and 49.8% (236/474) in the later period; mixed effect model p < 0.0001, odds ratio, 3.37 (95% CI: 2.32–4.89)]. Overall survival was significantly worse in the group with AEs ≥ Grade 3 than in the group without AEs ≥ Grade 3 [HR (95% CI) = 0.48 (0.36–0.65), p = 0.0001]. During the COVID- 19 pandemic, it became clear that the incidence of severe AEs (including irAEs) increased after ICI administration, particularly during the later period of the disease. Various factors may be associated with occurrence of severe AEs after ICI administration, and long-term careful observation and prospective multicenter clinical studies are required. |
| format | Article |
| id | doaj-art-a000b91ae6434ffb9c4e8cb0f2551246 |
| institution | OA Journals |
| issn | 1471-2172 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Immunology |
| spelling | doaj-art-a000b91ae6434ffb9c4e8cb0f25512462025-08-20T02:24:29ZengBMCBMC Immunology1471-21722025-04-0126111110.1186/s12865-025-00711-wIncidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemicSakiko Kimura0Hiroo Katsuya1Chiho Nakashima2Naoko Sueoka-Aragane3Koji Hayashida4Kazumi Sasaki5Rintaro Sogawa6Tatsuya Furuno7Moriyasu Yamauchi8Yoichiro Sugiyama9Hirokazu Noshiro10Motohiro Esaki11Mitsuru Noguchi12Hirokazu Takahashi13Keizo Anzai14Masatoshi Yokoyama15Kazunari Sugita16Yoshio Yamashita17Atsushi Kawaguchi18Shinya Kimura19Chisato Shimanoe20Department of Pharmacy, Saga University HospitalDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDepartment of Medical Information, Saga University HospitalCancer Center, Saga University HospitalDepartment of Pharmacy, Saga University HospitalDepartment of Pharmacy, Saga University HospitalDepartment of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Saga UniversityDepartment of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Saga UniversityDepartment of Surgery, Faculty of Medicine, Saga UniversityDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDepartment of Urology, Faculty of Medicine, Saga UniversityLiver Center, Faculty of Medicine, Saga University Hospital, Saga UniversityDivision of Metabolism and Endocrinology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Saga UniversityDivision of Dermatology, Department Of Internal Medicine, Faculty of Medicine, Saga UniversityDepartment of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga UniversityEducation and Research Center for Community Medicine, Faculty of Medicine, Saga UniversityDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga UniversityDepartment of Pharmacy, Saga University HospitalAbstract Immune-checkpoint inhibitors (ICIs) can cause inflammation and immune-related adverse events (irAEs). Although irAEs may be caused by dysregulation of cytokines, the impact of various COVID- 19-related factors on expression of ICI-related AEs remains unclear. Assessment of AEs following ICI administration during the COVID- 19 pandemic may provide valuable insights that enable optimization of patient selection, thereby maximizing the benefits of ICI therapy. The aim of this study was to investigate the actual occurrence of severe AEs after ICI administration during the COVID- 19 pandemic. The medical records of patients who received ICI at Saga University Hospital were examined retrospectively. The primary endpoint was the incidence of all AEs ≥ Grade 3 that occurred after ICI administration. The survey period, from Jan 2020 to Dec 2022, was divided into an earlier (Jan 2020–March 2021) and a later (April 2021–Dec 2022) period. AEs with a clear cause other than ICI were excluded from the analysis. A total of 527 patients were included in the analysis, with a median follow-up of 422 days. During the COVID- 19 pandemic, the incidence of AEs ≥ Grade 3 after ICI administration was 52.8%. The incidence of AEs ≥ Grade 3 AEs after ICI administration was significantly higher during the later period [23.4% (57/244) in the earlier period and 49.8% (236/474) in the later period; mixed effect model p < 0.0001, odds ratio, 3.37 (95% CI: 2.32–4.89)]. Overall survival was significantly worse in the group with AEs ≥ Grade 3 than in the group without AEs ≥ Grade 3 [HR (95% CI) = 0.48 (0.36–0.65), p = 0.0001]. During the COVID- 19 pandemic, it became clear that the incidence of severe AEs (including irAEs) increased after ICI administration, particularly during the later period of the disease. Various factors may be associated with occurrence of severe AEs after ICI administration, and long-term careful observation and prospective multicenter clinical studies are required.https://doi.org/10.1186/s12865-025-00711-wImmune-checkpoint inhibitorAdverse eventsCOVID- 19 pandemic |
| spellingShingle | Sakiko Kimura Hiroo Katsuya Chiho Nakashima Naoko Sueoka-Aragane Koji Hayashida Kazumi Sasaki Rintaro Sogawa Tatsuya Furuno Moriyasu Yamauchi Yoichiro Sugiyama Hirokazu Noshiro Motohiro Esaki Mitsuru Noguchi Hirokazu Takahashi Keizo Anzai Masatoshi Yokoyama Kazunari Sugita Yoshio Yamashita Atsushi Kawaguchi Shinya Kimura Chisato Shimanoe Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic BMC Immunology Immune-checkpoint inhibitor Adverse events COVID- 19 pandemic |
| title | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic |
| title_full | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic |
| title_fullStr | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic |
| title_full_unstemmed | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic |
| title_short | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic |
| title_sort | incidence of severe adverse events in cancer patients after treatment with immune checkpoint inhibitors during the covid 19 pandemic |
| topic | Immune-checkpoint inhibitor Adverse events COVID- 19 pandemic |
| url | https://doi.org/10.1186/s12865-025-00711-w |
| work_keys_str_mv | AT sakikokimura incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT hirookatsuya incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT chihonakashima incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT naokosueokaaragane incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT kojihayashida incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT kazumisasaki incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT rintarosogawa incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT tatsuyafuruno incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT moriyasuyamauchi incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT yoichirosugiyama incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT hirokazunoshiro incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT motohiroesaki incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT mitsurunoguchi incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT hirokazutakahashi incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT keizoanzai incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT masatoshiyokoyama incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT kazunarisugita incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT yoshioyamashita incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT atsushikawaguchi incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT shinyakimura incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic AT chisatoshimanoe incidenceofsevereadverseeventsincancerpatientsaftertreatmentwithimmunecheckpointinhibitorsduringthecovid19pandemic |